Disparities in clinical trial participation in ovarian cancer : A real-world analysis
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Significant disparities exist in clinical trial participation in non-gynecologic cancers, but little is known about disparities in ovarian cancer trial participation. Our objective was to examine patient, sociodemographic (race/ethnicity, insurance), cancer, and health system factors associated with clinical trial participation in ovarian cancer.
METHODS: We conducted a retrospective cohort study of patients with epithelial ovarian cancer diagnosed from 2011 to 2021, using a real-world electronic health record derived database, representing around 800 sites of care in US academic and community practices. We used multivariable Poisson regression modeling to analyze the association of ever participating in an ovarian cancer clinical drug trial with patient, sociodemographic, health system, and cancer factors.
RESULTS: Of the 7540 patients with ovarian cancer, 5.0% (95% CI 4.5-5.5) ever participated in a clinical drug trial. Patients of Hispanic or Latino ethnicity were 71% less likely to participate in clinical trials (RR 0.29, 95% CI 0.13-0.61) than non-Hispanic patients, and patients whose race was unknown or other than Black or White were 40% less likely to participate in clinical trials (RR 0.68, 95% CI 0.52-0.89). Patients who had Medicaid insurance were 51% less likely (RR 0.49, 95% CI 0.28-0.87) and those with Medicare were 32% (RR 0.48-0.97) less likely to participate in clinical trials than privately-insured patients.
CONCLUSION: In this national cohort study, only 5% of patients with ovarian cancer participated in clinical drug trials. Interventions are needed to decrease race, ethnicity, and insurance disparities in clinical trial participation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
---|---|
Enthalten in: |
Gynecologic oncology - 175(2023) vom: 01. Aug., Seite 25-31 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Smith, Anna Jo Bodurtha [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 30.07.2023 Date Revised 30.07.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ygyno.2023.05.066 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35802739X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35802739X | ||
003 | DE-627 | ||
005 | 20231226073851.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ygyno.2023.05.066 |2 doi | |
028 | 5 | 2 | |a pubmed24n1193.xml |
035 | |a (DE-627)NLM35802739X | ||
035 | |a (NLM)37300995 | ||
035 | |a (PII)S0090-8258(23)00319-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Smith, Anna Jo Bodurtha |e verfasserin |4 aut | |
245 | 1 | 0 | |a Disparities in clinical trial participation in ovarian cancer |b A real-world analysis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.07.2023 | ||
500 | |a Date Revised 30.07.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Significant disparities exist in clinical trial participation in non-gynecologic cancers, but little is known about disparities in ovarian cancer trial participation. Our objective was to examine patient, sociodemographic (race/ethnicity, insurance), cancer, and health system factors associated with clinical trial participation in ovarian cancer | ||
520 | |a METHODS: We conducted a retrospective cohort study of patients with epithelial ovarian cancer diagnosed from 2011 to 2021, using a real-world electronic health record derived database, representing around 800 sites of care in US academic and community practices. We used multivariable Poisson regression modeling to analyze the association of ever participating in an ovarian cancer clinical drug trial with patient, sociodemographic, health system, and cancer factors | ||
520 | |a RESULTS: Of the 7540 patients with ovarian cancer, 5.0% (95% CI 4.5-5.5) ever participated in a clinical drug trial. Patients of Hispanic or Latino ethnicity were 71% less likely to participate in clinical trials (RR 0.29, 95% CI 0.13-0.61) than non-Hispanic patients, and patients whose race was unknown or other than Black or White were 40% less likely to participate in clinical trials (RR 0.68, 95% CI 0.52-0.89). Patients who had Medicaid insurance were 51% less likely (RR 0.49, 95% CI 0.28-0.87) and those with Medicare were 32% (RR 0.48-0.97) less likely to participate in clinical trials than privately-insured patients | ||
520 | |a CONCLUSION: In this national cohort study, only 5% of patients with ovarian cancer participated in clinical drug trials. Interventions are needed to decrease race, ethnicity, and insurance disparities in clinical trial participation | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
700 | 1 | |a Alvarez, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Heintz, Jonathan |e verfasserin |4 aut | |
700 | 1 | |a Simpkins, Fiona |e verfasserin |4 aut | |
700 | 1 | |a Ko, Emily M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Gynecologic oncology |d 1972 |g 175(2023) vom: 01. Aug., Seite 25-31 |w (DE-627)NLM000614610 |x 1095-6859 |7 nnns |
773 | 1 | 8 | |g volume:175 |g year:2023 |g day:01 |g month:08 |g pages:25-31 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ygyno.2023.05.066 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 175 |j 2023 |b 01 |c 08 |h 25-31 |